Demet ILHAN ALGIN
(Eskişehir Osmangazi Üniversitesi)
Suna DAGLI ATALAY
(Eskişehir Osmangazi Üniversitesi)
SERHAT ÖZKAN
(Eskişehir Osmangazi Üniversitesi)
Demet OZBABALIK ADAPINAR
(Eskişehir Osmangazi Üniversitesi)
Yıl: 2017Cilt: 34Sayı: 3ISSN: 1300-1817 / 1302-1664Sayfa Aralığı: 231 - 241İngilizce

87 3
The Effect of Memantine on Cognitive Performance with Amnestic Mild Cognitive Impairment
Amaç: Amnestik hafif kognitif bozukluk (aMCI) normal bilişsel gerileme ve çok erken demans döneminde ortaya çıkan bilişsel değişimleri ifade eder. Biz aMCI hastalarında tedavide kullanılan memantin etkinliğini değerlendirmeyi amaçladık. Metod: Tüm hastalara Petersen kriterlerine göre aMCI tanısı kondu ve üç gruba ayrıldı. Grup 1, muayene sonrası memantin başlanan hastalardan oluştu (n=23), Grup 2'de muayene sonrası memantin tedavisi almayan hastalar (n=22), Grup 3 sağlıklı yaşa uygun gönüllülerden (n=20) oluşuyordu. Muayeneleri takiben demans polikliniğimizde kullanılan Turkuaz Alzheimer Çalışma Grubu veri tabanından nöropsikiyatrik testler yapıldı. Sonuçlar: Hastaların yaş ortalaması Grup 1'de 66±7.04, Grup 2'de 65.3±6.20 ve Grup 3'te 57.6±5.40 idi. Grup 1'deki en belirgin iyileşme Mini Mental Durum Muayenesinde (MMSE), Wechsler bellek ölçeği alt grup testleri, Blessed Demans Derecelendirme Ölçeği (BDRS), Boston adlandırma testinde (BNT) görüldü (p<0.05). Memantinin tedavisi, 24 haftalık çalışma süresi boyunca Geriatrik Demans Ölçeği skorlarında düzelme ile ilişkiliydi. Tartışma: Bu sonuçlar memantinin aMCI hastalarında tedavi almayan grupla karşılaştırıldığında bilişsel işlevsellik düzeyini artırdığını göstermektedir. Bu bulgular, plasebo kontrollü daha geniş randomize bir çalışmaya ihtiyaç olduğunu ortaya koymaktadır
Fen > Tıp > Nörolojik Bilimler
DergiAraştırma MakalesiErişime Açık
  • 1. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551-2561.
  • 2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194.
  • 3. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005; 62:1160-1163.
  • 4. Edmonds EC, Delano-Wood L, Clark LR, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false positive diagnostic errors. Alzheimers Dement 2015; 11:415-424.
  • 5. Eshkoor SA, Hamid TA, Mun CY, Ng CK. Mild cognitive impairment and its management in older people. Clin Interv Aging 2015;10:687-693.
  • 6. Jak AJ, Preis SR, Beiser AS, et al. Neuropsychological Criteria for Mild Cognitive Impairment and Dementia Risk in the Framingham Heart Study. J Int Neuropsychol Soc 2016;9:937- 943.
  • 7. Buse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC. Subclassifications for mild cognitive impairment : Prevalence and predictive validity. Psychol Med 2003;33: 1029-1038.
  • 8. Peskind ER, Potkin SG, Pomara N, et al.Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-715.
  • 9. Fitzpatrick-Lewis D, Warren R, Ali MU, Sherifali D, Raina P. Treatment for mild cognitive impairment: a systematic review and meta-analysis. CMAJ Open 2015;3:19-27.
  • 10. Fellgiebel A. Alzheimer drugs for mild cognitive impairment. Neuropsychiatry 2007;21:230-233.
  • 11. Folstein M, Folstein S, McHugh P. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
  • 12. Wechsler D. Wechsler Memory Scale-Revised manual. New York: Psychological Corporation, 1987.
  • 13. LaBarge E, Edwards D, Knesevich JW.Performance of normal elderly on the Boston Naming Test. Brain Lang 1986;273:80-84.
  • 14. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA. Clock drawing in Alzheimer`s disease. A novel measure of dementia severity. Journal Am Geriatr Soc 1989;37:725-729.
  • 15. Blessed G, Tomlinsin B, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Brit J Psychiatry 1968;114:797-811.
  • 16. Thal LJ, Grundman M, Golden R.Alzheimer´s disease:a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam.Neurology 1986;36:262- 264.
  • 17. Lawton MP, Brody EM. Assessment of older people: self maintainning and instrumental activities of daily living. Gerontologist 1969;9:179- 186.
  • 18. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
  • 19. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS):Recent evidence and development of a shorter version. 1986. Clinical Gerontology: A Guide to Assessment and Intervention.The Haworth Press: New York; 165-173.
  • 20. Petersen RC. Mild cognitive impairment. Continuum. Dementia 2004;10:9-28.
  • 21. Morris JC. Challenging assumptions about Alzheimer`s Disease: mild cognitive impirment and the cholinergic hypothesis. Ann Neurology 2002;51:143-144.
  • 22. Ashford JW. Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions.J Alzheimers Dis 2015;47:149-156.
  • 23. Palmer A, Gershon S.Is the neuronal basis of Alzheimer"s disease cholinergic or glutamatergic ? FASEB Journal 1990;4:2745-2752.
  • 24. Muller W,Mutschler E, Riederer P. Noncompetitive NMDA reseptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer"s dementia. Pharmacopsychiatry 1995;28:113-124.
  • 25. Winblad B,Jones RW,Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer`´s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cognition Disorders 2007;24:20-27.
  • 26. Zhang N, Wei C, Du H, Shi FD, Cheng Y. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in MildtoModerate Alzheimer`s Disease Patients. Dement Geriatr Cogn Disord 2015;40:85-93.
  • 27. Hort J, O`Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer"s disease. Eur J Neurol 2010;17:1236- 1248.
  • 28. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-2388.
  • 29. Farlow MR. Treatment of mild cognitive impairment (MCI). Curr Alzheimer Res 2009;6:362-367.
  • 30. Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging;Alzheimer Association. The new 2011 recommendations of the National Institute on aging and the Alzheimer`s Association on diagnostic guidelines for Alzheimer"s disease: Preclinical stages, mild cognitive impairment and dementia. Rev Neurol (Paris).2012;168:471-482.
  • 31. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;25:CD001747.
  • 32. Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012;16:544-548.
  • 33. Rabin LA, Pare N, Saykin AJ,et al.. Differential memory test sensitivity for diagnosing amnestic mild cognitive impairment and predicting conversion to Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2009;16:357-376.
  • 34. Liu Y, Cai ZL, Xue S, Zhou X, Wu F.Proxies of cognitive reserve and their effects on neuropsychological performance in patients with mild cognitive impairment. J Clinical Neurosci 2013;20:548-553.
  • 35. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-contolled trial. Neurology 2004;63:651-657.
  • 36. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551-2561
  • 37. Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013;203:255- 264.
  • 38. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024- 2035.
  • 39. Pelton GH, Harper OL, Roose SP, Marder K, D`Antonio K, Devanand DP. Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2016;31:648-655.
  • 40. Ramaswamy S, Madabushi J, Hunziker J, Bhatia SC, Petty F. An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorders.J Aging Res Epub 2015 May 12.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.